CHROMADEX CORP (CDXC) Stock Fundamental Analysis
USA - NASDAQ:CDXC - US1710774076 - Common Stock
7.87 USD
-0.07 (-0.88%)
7.87 USD
0 (0%)
Taking everything into account, CDXC scores 6 out of 10 in our fundamental rating. CDXC was compared to 57 industry peers in the Life Sciences Tools & Services industry. CDXC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CDXC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
CDXC had positive earnings in the past year.
In the past year CDXC had a positive cash flow from operations.
In the past 5 years CDXC reported 4 times negative net income.
In multiple years CDXC reported negative operating cash flow during the last 5 years.
1.2 Ratios
CDXC's Return On Assets of 12.52% is amongst the best of the industry. CDXC outperforms 90.91% of its industry peers.
CDXC has a Return On Equity of 18.55%. This is amongst the best in the industry. CDXC outperforms 90.91% of its industry peers.
CDXC has a Return On Invested Capital of 12.13%. This is amongst the best in the industry. CDXC outperforms 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROIC | 12.13% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDXC's Profit Margin of 8.58% is fine compared to the rest of the industry. CDXC outperforms 74.55% of its industry peers.
With a decent Operating Margin value of 7.76%, CDXC is doing good in the industry, outperforming 63.64% of the companies in the same industry.
CDXC has a Gross Margin of 61.84%. This is amongst the best in the industry. CDXC outperforms 87.27% of its industry peers.
In the last couple of years the Gross Margin of CDXC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CDXC is still creating some value.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
CDXC has more shares outstanding than it did 5 years ago.
CDXC has a better debt/assets ratio than last year.
2.2 Solvency
CDXC has an Altman-Z score of 15.46. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
CDXC's Altman-Z score of 15.46 is amongst the best of the industry. CDXC outperforms 100.00% of its industry peers.
There is no outstanding debt for CDXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.46 |
ROIC/WACC1.11
WACC10.97%
2.3 Liquidity
A Current Ratio of 3.57 indicates that CDXC has no problem at all paying its short term obligations.
CDXC's Current ratio of 3.57 is in line compared to the rest of the industry. CDXC outperforms 54.55% of its industry peers.
A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
The Quick ratio of CDXC (3.06) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 242.86% over the past year.
Looking at the last year, CDXC shows a quite strong growth in Revenue. The Revenue has grown by 19.17% in the last year.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
3.2 Future
Based on estimates for the next years, CDXC will show a very strong growth in Earnings Per Share. The EPS will grow by 43.55% on average per year.
CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
CDXC is valuated quite expensively with a Price/Earnings ratio of 78.70.
The rest of the industry has a similar Price/Earnings ratio as CDXC.
CDXC is valuated expensively when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
CDXC is valuated quite expensively with a Price/Forward Earnings ratio of 66.13.
The rest of the industry has a similar Price/Forward Earnings ratio as CDXC.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.92, CDXC is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 |
4.2 Price Multiples
CDXC's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CDXC is cheaper than 61.82% of the companies in the same industry.
CDXC's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CDXC is cheaper than 65.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.22 | ||
| EV/EBITDA | 66.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CDXC has a very decent profitability rating, which may justify a higher PE ratio.
CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%
5. Dividend
5.1 Amount
CDXC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.87
-0.07 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner Change0.25%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 | ||
| P/S | 6.14 | ||
| P/FCF | 51.22 | ||
| P/OCF | 50.53 | ||
| P/B | 13.27 | ||
| P/tB | 13.38 | ||
| EV/EBITDA | 66.44 |
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROCE | 15.35% | ||
| ROIC | 12.13% | ||
| ROICexc | 104.84% | ||
| ROICexgc | 111.73% | ||
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% | ||
| FCFM | 11.99% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 20.02% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 7726 | ||
| Cash Conversion | 141.79% | ||
| Profit Quality | 139.72% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z | 15.46 |
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A
CHROMADEX CORP / CDXC FAQ
What is the fundamental rating for CDXC stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDXC.
What is the valuation status for CDXC stock?
ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.
Can you provide the profitability details for CHROMADEX CORP?
CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.
What are the PE and PB ratios of CHROMADEX CORP (CDXC) stock?
The Price/Earnings (PE) ratio for CHROMADEX CORP (CDXC) is 78.7 and the Price/Book (PB) ratio is 13.27.
How financially healthy is CHROMADEX CORP?
The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.